Retrospective data has shown that NSCLC patients with ex20ins were associated with lower PD-L1 expression and tumour mutational burden and a poor response to immunotherapy compared with NSCLC patients without targetable mutations [30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.